Inolitazone (dihydrochloride)

Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.

Product Specifications

CAS Number

[223132-38-5]

Product Name Alternative

Efatutazone (dihydrochloride) ; CS-7017 (dihydrochloride) ; RS5444 (dihydrochloride)

UNSPSC

12352005

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/inolitazone-dihydrochloride.html

Purity

98.86

Solubility

DMSO : 2 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : < 0.1 mg/mL

Smiles

O=C(N1)SC(CC2=CC=C(OCC3=NC4=CC=C(OC5=CC(C)=C(N)C(C)=C5)C=C4N3C)C=C2)C1=O.Cl.Cl

Molecular Formula

C27H28Cl2N4O4S

Molecular Weight

575.51

References & Citations

[1]Copland JA, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13;25 (16) :2304-17.|[2]Marlow LA, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009 Feb 15;69 (4) :1536-44.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

PPARγ

Citation 01

BioRxiv. 2025 Oct 22.|Cancer Med. 2018 May;7 (5) :1955-1966. |Int J Oncol. 2018 Jun;52 (6) :1991-2000. |Exp Cell Res. 2017 Dec 15;361 (2) :246-256. |Front Microbiol. 2019 Jan 8:9:3257.